Title |
Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy
|
---|---|
Published in |
Cancer Immunology, Immunotherapy, July 2017
|
DOI | 10.1007/s00262-017-2040-9 |
Pubmed ID | |
Authors |
Frida Ewald Sander, Malin Nilsson, Anna Rydström, Johan Aurelius, Rebecca E. Riise, Charlotta Movitz, Elin Bernson, Roberta Kiffin, Anders Ståhlberg, Mats Brune, Robin Foà, Kristoffer Hellstrand, Fredrik B. Thorén, Anna Martner |
Abstract |
Regulatory T cells (Tregs) have been proposed to dampen functions of anti-neoplastic immune cells and thus promote cancer progression. In a phase IV trial (Re:Mission Trial, NCT01347996, http://www.clinicaltrials.gov ) 84 patients (age 18-79) with acute myeloid leukemia (AML) in first complete remission (CR) received ten consecutive 3-week cycles of immunotherapy with histamine dihydrochloride (HDC) and low-dose interleukin-2 (IL-2) to prevent relapse of leukemia in the post-consolidation phase. This study aimed at defining the features, function and dynamics of Foxp3(+)CD25(high)CD4(+) Tregs during immunotherapy and to determine the potential impact of Tregs on relapse risk and survival. We observed a pronounced increase in Treg counts in peripheral blood during initial cycles of HDC/IL-2. The accumulating Tregs resembled thymic-derived natural Tregs (nTregs), showed augmented expression of CTLA-4 and suppressed the cell cycle proliferation of conventional T cells ex vivo. Relapse of AML was not prognosticated by Treg counts at onset of treatment or after the first cycle of immunotherapy. However, the magnitude of Treg induction was diminished in subsequent treatment cycles. Exploratory analyses implied that a reduced expansion of Tregs in later treatment cycles and a short Treg telomere length were significantly associated with a favorable clinical outcome. Our results suggest that immunotherapy with HDC/IL-2 in AML entails induction of immunosuppressive Tregs that may be targeted for improved anti-leukemic efficiency. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 51 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 9 | 18% |
Student > Master | 8 | 16% |
Student > Ph. D. Student | 6 | 12% |
Other | 4 | 8% |
Student > Doctoral Student | 3 | 6% |
Other | 10 | 20% |
Unknown | 11 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 14 | 27% |
Biochemistry, Genetics and Molecular Biology | 9 | 18% |
Immunology and Microbiology | 6 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 10% |
Nursing and Health Professions | 1 | 2% |
Other | 5 | 10% |
Unknown | 11 | 22% |